Indexado en

Licencia y uso

Citaciones

Cited 4 times in

Cited 1 times in

Altmetrics

Grant support

This work was supported by Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK, The Scientific and Technological Research Council of Turkiye) with project coded 1002-222M436 (2022-2023). The authors would like to acknowledge that this paper is submitted in partial fulfilment of the requirements for PhD degree at Yildiz Technical University. Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work the author(s) used GPT-3.5/OpenAI in order to improve readability and language. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

Análisis de autorías institucional

Compartir

Advanced Bioresin Formulation for 3D-Printed Bone Scaffolds: PCLDMA and p-PLA Integration

Publicado en:Polymers. 16 (4): 534- - 2024-02-01 16(4), DOI: 10.3390/polym16040534

Autores: Sakarya, Deniz; Zorlu, Tolga; Yucel, Sevil; Sahin, Yesim Muge; Ozarslan, Ali Can

Afiliaciones

Resumen

In bone tissue engineering, scaffold attributes such as pore dimensions and mechanical strength are crucial. This study synthesized polycaprolactone dimethacrylate (PCLDMA) from polycaprolactone (PCL), incorporating epichlorohydrin (Epi-PCL) and methacryloyl chloride (Meth-Cl). PCLDMA was blended with polylactic acid (p-PLA) to 3D-print bone scaffolds using stereolithography (SLA). Analytical techniques included nuclear magnetic resonance (NMR), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and compression testing. Degradation kinetics and cell viability were investigated using human osteoblast (HOB) cells. Findings revealed PCLDMA/p-PLA composite scaffold superiority over the original polymers. Notably, PCLDMA-60 (60% PCLDMA, 40% p-PLA) displayed optimal properties. Compressive strength varied from 0.019 to 16.185 MPa, porosity from 2% to 50%, and degradation rates from 0% to 0.4% over three days. Cell viability assays affirmed biocompatibility across various PCLDMA ratios. In conclusion, PCLDMA/p-PLA composite scaffolds, particularly PCLDMA-60, show great potential in bone tissue engineering.

Palabras clave